Mediar raises $105 million to target fibrotic mediators

Fibrosis-focused Mediar Therapeutics has added $105 million to its coffers.

The US firm’s fundraising includes an $85 million Series A round co-led by Novartis Venture Fund and Sofinnova Partners and with participation from Pfizer Ventures, Mission BioCapital, Gimv, Pureos, Bristol Myers Squibb (NYSE: BMY), Eli Lilly (NYSE: LLY), Ono Venture Investment and Mass General Brigham Ventures.

Access the article on (paywall)